Cited by 85Tuberous Sclerosis Complex ResearchGenetics and Neurodevelopmental DisordersPI3K/AKT/mTOR signaling in cancer

Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex

Open access
Tsai, Peter, Sahin, Mustafa·2011·Current Opinion in Neurology

Abstract

PURPOSE OF REVIEW: Mendelian disorders that affect cognition provide a unique opportunity to study the mechanisms of neurodevelopmental disorders through the examination of genetic defects in animals and development of hypotheses that can be tested in human beings. Tuberous sclerosis complex (TSC) is a genetic disease that presents with epilepsy, autism, and intellectual disability. Here we review recent advances in our understanding of TSC pathogenesis and signaling pathways that may be modulated to treat the neurological symptoms. RECENT FINDINGS: Accumulating evidence suggests that TSC patients have nontuber abnormalities that contribute to the development of the neurological phenotype- in particular, disorganization of axon tracts and deficient myelination. TSC mouse models have failed to replicate the human neuropathology entirely, but have shed light on the cellular abnormalities and the neurobehavioral phenotypes. Most importantly, cell culture and animal models have identified the mTORC1 pathway as a therapeutic target in this disease. SUMMARY: Preclinical data strongly suggest that TSC is a disease of abnormal neuronal connectivity. The high incidence of neurodevelopmental deficits, early detection of the disease in very young ages, and availability of mTORC1 inhibitors make TSC a model for other Mendelian disorders of neurocognition and an avenue for the mechanism-based treatment trials of neurodevelopmental disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wco.0b013e32834451c4

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several monogenic causes of ASD, including TSC and Joubert Syndrome, show abnormal axon path finding or migration abnormalities known to lead to altered brain structural connectivity.

    “Indeed several of the monogenic causes of ASD, including TSC [56] and Joubert Syndrome [57, 58] show manifestations of abnormal axon path finding or migration abnormalities that are known to lead to alterations in brain structural connectivity.”

    From Genetics of autism spectrum disorders (2011) · cites this paper as [56]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 67 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Tsai, P., & Sahin, M.
Affiliations
Boston Children's Hospital (US)
Venue
Current Opinion in Neurology
Published
2011-04
Volume
24
Issue
2
Pages
106-113
ISSN
1350-7540 (ISSN-L)
OpenAlex
W2014945127
Cited by
84
References
67
Citations by year
2026: 3 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 8 · 2014: 9 · 2013: 13 · 2012: 9
FWCI
1.13
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Nancy Lurie Marks Family Foundation
  • Manton Foundation
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (R01NS058956, T32NS007473)
Topics
  • Health Sciences › Medicine › Physiology › Tuberous Sclerosis Complex Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
tuberous sclerosis complex, neurocognitive impairment, mTORC1 signaling, mTORC1 inhibitors, neuronal connectivity, neurodevelopmental disorders, intellectual disability, epilepsy, autism spectrum disorder
MeSH terms
Abnormalities, Multiple, Mechanistic Target of Rapamycin Complex 1, Animals, Cognition Disorders, Disease Models, Animal, Humans, Neurons, Proteins, Tuberous Sclerosis, Signal Transduction, Multiprotein Complexes, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review